In a remarkably short time since its development, high-throughput CRISPR screening has revolutionized functional genomics and drug discovery. CRISPR screening applications and technology adaptations have increased and evolved, now becoming a core engine for both novel drug discovery and for driving new therapies to the patient more quickly and precisely. Recent developments have now enabled researchers to bring these approaches to primary human immune cells, where there is a high potential for the discovery of new cell therapy strategies.

In this webinar, Eric Shifrut, postdoctoral fellow at UCSF, and Benedict Cross, Head of Functional Genomic Screening at Horizon, presented the principles, strategies and experimental outcomes of CRISPR screening, including screening in primary T cells.